<DOC>
	<DOCNO>NCT00996359</DOCNO>
	<brief_summary>RATIONALE : Giving low-dose total-body irradiation donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . PURPOSE : This phase I trial study side effect donor stem cell transplant total-body irradiation see well work treat patient relapsed refractory hematologic cancer acute myeloid leukemia acute lymphocytic leukemia complete remission .</brief_summary>
	<brief_title>Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate toxicity irradiated haploidentical allogeneic cellular therapy low-dose total-body irradiation pharmacologic graft-vs-host disease prophylaxis patient relapse refractory hematologic malignancy patient acute myeloid leukemia ( AML ) acute lymphoblastic leukemia second great complete remission ( CR2 ) . Secondary - To evaluate immunologic parameter haploidentical therapy . - To demonstrate host anti-leukemia T-cells subset patient AML HLA-A2-positive . - To observe evidence antitumor activity within confines pilot study and/or assess duration remission patient enter study CR2 . OUTLINE : Patients undergo low-dose total-body irradiation infusion irradiate donor cell day 0 . Patients also receive filgrastim subcutaneously ( SC ) daily pegfilgrastim SC every 14 day start day 1 . Patients complete remission ( CR ) persistent disease undergo irradiate donor lymphocyte infusion ( DLI ) 8 week . Repeat irradiate DLI administer patient remain CR achieve stable respond disease second infusion ( confirm histologic assessment ) third infusion ( confirm radiographic assessment ) . DLI repeat every 8 week pending disease clinical status total 6 infusion 12-month period . Blood sample collect baseline , upon recovery count , monthly thereafter immunologic study . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients 18 year old must meet following criterion : Histologically confirm hematologic malignancy candidate standard allogeneic transplantation Highrisk disease , include : Refractory/relapsed acute myeloid leukemia ( AML ) AML second great completion remission ( CR2 ) Relapsed refractory acute lymphoblastic leukemia ( ALL ) ALL CR2 Tyrosine kinase inhibitorresistant chronic myelogenous leukemia chronic , accelerate , blast crisis Fludarabineresistant chronic lymphocytic leukemia Highrisk myelodysplastic syndrome ( MDS ) ( i.e. , MDS score ≥ 1.5 International Scoring System ) Chronic myelomonocytic leukemia Relapsed diffuse large cell nonHodgkin lymphoma ( NHL ) measurable disease ( eligible ) highdose chemotherapy/autologous hematopoietic stem cell ( HSC ) rescue allogeneic hematopoietic stem cell transplantation ( HSCT ) Relapsed follicular NHL , mantle cell lymphoma , lowgrade histology NHL measurable disease ( eligible ) highdose chemotherapy/autologous HSC rescue allogeneic HSCT Relapsed refractory highgrade/aggressive NHL ( Burkitt lymphoma , lymphoblastic lymphoma , Tcell lymphoma , NKlike lymphoma ) measurable disease ( eligible ) highdose chemotherapy/autologous HSC rescue allogeneic HSCT Hodgkin lymphoma measurable disease ( eligible ) highdose chemotherapy/autologous HSC rescue allogeneic HSCT Relapsed refractory multiple myeloma ( eligible ) highdose chemotherapy/autologous HSC rescue follow salvage therapy thalidomide , lenalidomide , bortezomib FDAapproved multiple myeloma salvage therapy Patients 1317 year old must meet following criterion : Histologically confirm hematologic malignancy candidate standard allogeneic transplantation Highrisk disease , include : Refractory/relapsed AML AML CR2 Relapsed refractory ALL ALL CR2 Relapsed diffuse large cell NHL measurable disease ( eligible ) highdose chemotherapy/autologous HSC rescue allogeneic HSCT Relapsed follicular NHL , mantle cell lymphoma ( lowgrade histology NHL ) measurable disease ( eligible ) highdose chemotherapy/autologous HSC rescue allogeneic HSCT Relapsed refractory highgrade/aggressive NHL ( Burkitt lymphoma , lymphoblastic lymphoma , Tcell lymphoma , NKlike lymphoma ) measurable disease ( eligible ) highdose chemotherapy/autologous HSC rescue allogeneic HSCT Hodgkin lymphoma measurable disease ( eligible ) highdose chemotherapy/autologous HSC rescue allogeneic HSCT Eligible haploidentical irradiate cellular therapy No known active brain metastasis malignant meningitis Available partially ( ≥ 3/6 class I antigen ) HLAmatched ( serology ) relate donor NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 60100 % ( patient &gt; 16 year ) Lansky PS 60100 % ( patient ≤ 16 year ) Patients unable walk paralysis wheelchair consider ambulatory purpose assess PS Patients ≥ 18 year : Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ( unless attributable Gilbert disease ) DLCO/alveolar volume &gt; 50 % Serum creatinine &lt; 2.0 mg/dL Patients 1317 year : Creatinine clearance radioisotope GFR ≥ 70 mL/min OR serum creatinine base age/gender follow : 13 &lt; 16 year : 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ≥ 16 year : 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) AST/ALT ≤ 2.5 time ULN age Total bilirubin &lt; 2.0 mg/dL ( unless attributable Gilbert syndrome ) Shortening fraction ≥ 27 % ECHO ejection fraction ≥ 50 % radionuclide angiogram FEV_1 , force vital capacity , DLCO correct hemoglobin ≥ 60 % pulmonary function test ( PFTs ) Children unable cooperate PFTs must meet following criterion : No evidence dyspnea rest No exercise intolerance No requirement supplemental oxygen therapy Any organ dysfunction think secondary disease consider separately patient eligible physician 's discretion Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception , , 24 week study treatment No known HIV positivity No history current prior medical problem , investigator 's opinion , would prevent administration study treatment assessment response due excess toxicity No active uncontrolled infection medical , psychological , social condition might increase likelihood patient adverse effect poor outcome PRIOR CONCURRENT THERAPY : See Disease Characteristics No corticosteroid within 2 week receive irradiated donor lymphocyte infusion No medication might increase likelihood patient adverse effect poor outcome</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>hepatosplenic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
</DOC>